The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow

Saumya Gurbani, Brent Weinberg, Lee Cooper, Eric Mellon, Eduard Schreibmann, Sulaiman Sheriff, Andrew Maudsley, Mohammed Goryawala, Hui Kuo Shu, Hyunsuk Shim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Glioblastoma has poor prognosis with inevitable local recurrence despite aggressive treatment with surgery and chemoradiation. Radiation therapy (RT) is typically guided by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) for defining the high-dose target and T2-weighted fluid-attenuation inversion recovery MRI for defining the moderate-dose target. There is an urgent need for improved imaging methods to better delineate tumors for focal RT. Spectroscopic MRI (sMRI) is a quantitative imaging technique that enables whole-brain analysis of endogenous metabolite levels, such as the ratio of choline-to-N-acetylaspartate. Previous work has shown that choline-to-N-acetylaspartate ratio accurately identifies tissue with high tumor burden beyond what is seen on standard imaging and can predict regions of metabolic abnormality that are at high risk for recurrence. To facilitate efficient clinical implementation of sMRI for RT planning, we developed the Brain Imaging Collaboration Suite (BrICS; https://brainimaging.emory.edu/brics-demo), a cloud platform that integrates sMRI with standard imaging and enables team members from multiple departments and institutions to work together in delineating RT targets. BrICS is being used in a multisite pilot study to assess feasibility and safety of dose-escalated RT based on metabolic abnormalities in patients with glioblastoma (Clinicaltrials.gov NCT03137888). The workflow of analyzing sMRI volumes and preparing RT plans is described. The pipeline achieved rapid turnaround time by enabling team members to perform their delegated tasks independently in BrICS when their clinical schedules allowed. To date, 18 patients have been treated using targets created in BrICS and no severe toxicities have been observed.

Original languageEnglish (US)
Pages (from-to)184-191
Number of pages8
JournalTomography (Ann Arbor, Mich.)
Volume5
Issue number1
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Workflow
Neuroimaging
Radiotherapy
Magnetic Resonance Imaging
Brain
Glioblastoma
Choline
Recurrence
Tumor Burden
Appointments and Schedules
Safety
Neoplasms

Keywords

  • cloud platform
  • radiation therapy
  • spectroscopic MRI

Cite this

The Brain Imaging Collaboration Suite (BrICS) : A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow. / Gurbani, Saumya; Weinberg, Brent; Cooper, Lee; Mellon, Eric; Schreibmann, Eduard; Sheriff, Sulaiman; Maudsley, Andrew; Goryawala, Mohammed; Shu, Hui Kuo; Shim, Hyunsuk.

In: Tomography (Ann Arbor, Mich.), Vol. 5, No. 1, 01.03.2019, p. 184-191.

Research output: Contribution to journalArticle

Gurbani, Saumya ; Weinberg, Brent ; Cooper, Lee ; Mellon, Eric ; Schreibmann, Eduard ; Sheriff, Sulaiman ; Maudsley, Andrew ; Goryawala, Mohammed ; Shu, Hui Kuo ; Shim, Hyunsuk. / The Brain Imaging Collaboration Suite (BrICS) : A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow. In: Tomography (Ann Arbor, Mich.). 2019 ; Vol. 5, No. 1. pp. 184-191.
@article{3831317e6b734fb18394270c6d2b937e,
title = "The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow",
abstract = "Glioblastoma has poor prognosis with inevitable local recurrence despite aggressive treatment with surgery and chemoradiation. Radiation therapy (RT) is typically guided by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) for defining the high-dose target and T2-weighted fluid-attenuation inversion recovery MRI for defining the moderate-dose target. There is an urgent need for improved imaging methods to better delineate tumors for focal RT. Spectroscopic MRI (sMRI) is a quantitative imaging technique that enables whole-brain analysis of endogenous metabolite levels, such as the ratio of choline-to-N-acetylaspartate. Previous work has shown that choline-to-N-acetylaspartate ratio accurately identifies tissue with high tumor burden beyond what is seen on standard imaging and can predict regions of metabolic abnormality that are at high risk for recurrence. To facilitate efficient clinical implementation of sMRI for RT planning, we developed the Brain Imaging Collaboration Suite (BrICS; https://brainimaging.emory.edu/brics-demo), a cloud platform that integrates sMRI with standard imaging and enables team members from multiple departments and institutions to work together in delineating RT targets. BrICS is being used in a multisite pilot study to assess feasibility and safety of dose-escalated RT based on metabolic abnormalities in patients with glioblastoma (Clinicaltrials.gov NCT03137888). The workflow of analyzing sMRI volumes and preparing RT plans is described. The pipeline achieved rapid turnaround time by enabling team members to perform their delegated tasks independently in BrICS when their clinical schedules allowed. To date, 18 patients have been treated using targets created in BrICS and no severe toxicities have been observed.",
keywords = "cloud platform, radiation therapy, spectroscopic MRI",
author = "Saumya Gurbani and Brent Weinberg and Lee Cooper and Eric Mellon and Eduard Schreibmann and Sulaiman Sheriff and Andrew Maudsley and Mohammed Goryawala and Shu, {Hui Kuo} and Hyunsuk Shim",
year = "2019",
month = "3",
day = "1",
doi = "10.18383/j.tom.2018.00028",
language = "English (US)",
volume = "5",
pages = "184--191",
journal = "Tomography (Ann Arbor, Mich.)",
issn = "2379-1381",
publisher = "Grapho Publications LLC",
number = "1",

}

TY - JOUR

T1 - The Brain Imaging Collaboration Suite (BrICS)

T2 - A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow

AU - Gurbani, Saumya

AU - Weinberg, Brent

AU - Cooper, Lee

AU - Mellon, Eric

AU - Schreibmann, Eduard

AU - Sheriff, Sulaiman

AU - Maudsley, Andrew

AU - Goryawala, Mohammed

AU - Shu, Hui Kuo

AU - Shim, Hyunsuk

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Glioblastoma has poor prognosis with inevitable local recurrence despite aggressive treatment with surgery and chemoradiation. Radiation therapy (RT) is typically guided by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) for defining the high-dose target and T2-weighted fluid-attenuation inversion recovery MRI for defining the moderate-dose target. There is an urgent need for improved imaging methods to better delineate tumors for focal RT. Spectroscopic MRI (sMRI) is a quantitative imaging technique that enables whole-brain analysis of endogenous metabolite levels, such as the ratio of choline-to-N-acetylaspartate. Previous work has shown that choline-to-N-acetylaspartate ratio accurately identifies tissue with high tumor burden beyond what is seen on standard imaging and can predict regions of metabolic abnormality that are at high risk for recurrence. To facilitate efficient clinical implementation of sMRI for RT planning, we developed the Brain Imaging Collaboration Suite (BrICS; https://brainimaging.emory.edu/brics-demo), a cloud platform that integrates sMRI with standard imaging and enables team members from multiple departments and institutions to work together in delineating RT targets. BrICS is being used in a multisite pilot study to assess feasibility and safety of dose-escalated RT based on metabolic abnormalities in patients with glioblastoma (Clinicaltrials.gov NCT03137888). The workflow of analyzing sMRI volumes and preparing RT plans is described. The pipeline achieved rapid turnaround time by enabling team members to perform their delegated tasks independently in BrICS when their clinical schedules allowed. To date, 18 patients have been treated using targets created in BrICS and no severe toxicities have been observed.

AB - Glioblastoma has poor prognosis with inevitable local recurrence despite aggressive treatment with surgery and chemoradiation. Radiation therapy (RT) is typically guided by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) for defining the high-dose target and T2-weighted fluid-attenuation inversion recovery MRI for defining the moderate-dose target. There is an urgent need for improved imaging methods to better delineate tumors for focal RT. Spectroscopic MRI (sMRI) is a quantitative imaging technique that enables whole-brain analysis of endogenous metabolite levels, such as the ratio of choline-to-N-acetylaspartate. Previous work has shown that choline-to-N-acetylaspartate ratio accurately identifies tissue with high tumor burden beyond what is seen on standard imaging and can predict regions of metabolic abnormality that are at high risk for recurrence. To facilitate efficient clinical implementation of sMRI for RT planning, we developed the Brain Imaging Collaboration Suite (BrICS; https://brainimaging.emory.edu/brics-demo), a cloud platform that integrates sMRI with standard imaging and enables team members from multiple departments and institutions to work together in delineating RT targets. BrICS is being used in a multisite pilot study to assess feasibility and safety of dose-escalated RT based on metabolic abnormalities in patients with glioblastoma (Clinicaltrials.gov NCT03137888). The workflow of analyzing sMRI volumes and preparing RT plans is described. The pipeline achieved rapid turnaround time by enabling team members to perform their delegated tasks independently in BrICS when their clinical schedules allowed. To date, 18 patients have been treated using targets created in BrICS and no severe toxicities have been observed.

KW - cloud platform

KW - radiation therapy

KW - spectroscopic MRI

UR - http://www.scopus.com/inward/record.url?scp=85071549694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071549694&partnerID=8YFLogxK

U2 - 10.18383/j.tom.2018.00028

DO - 10.18383/j.tom.2018.00028

M3 - Article

C2 - 30854456

AN - SCOPUS:85071549694

VL - 5

SP - 184

EP - 191

JO - Tomography (Ann Arbor, Mich.)

JF - Tomography (Ann Arbor, Mich.)

SN - 2379-1381

IS - 1

ER -